Risk of Malignancy in Patients with Asthma‐COPD Overlap Compared to Patients with COPD without Asthma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Risk of Malignancy in Patients with Asthma‐COPD Overlap Compared to Patients with COPD without Asthma. / Bonnesen, Barbara; Sivapalan, Pradeesh; Jordan, Alexander; Pedersen, Johannes Wirenfeldt; Bergsøe, Christina Marisa; Eklöf, Josefin; Toennesen, Louise Lindhardt; Jensen, Sidse Graff; Naqibullah, Matiullah; Saghir, Zaigham; Jensen, Jens Ulrik Stæhr.

In: Biomedicines, Vol. 10, No. 7, 1463, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bonnesen, B, Sivapalan, P, Jordan, A, Pedersen, JW, Bergsøe, CM, Eklöf, J, Toennesen, LL, Jensen, SG, Naqibullah, M, Saghir, Z & Jensen, JUS 2022, 'Risk of Malignancy in Patients with Asthma‐COPD Overlap Compared to Patients with COPD without Asthma', Biomedicines, vol. 10, no. 7, 1463. https://doi.org/10.3390/biomedicines10071463

APA

Bonnesen, B., Sivapalan, P., Jordan, A., Pedersen, J. W., Bergsøe, C. M., Eklöf, J., Toennesen, L. L., Jensen, S. G., Naqibullah, M., Saghir, Z., & Jensen, J. U. S. (2022). Risk of Malignancy in Patients with Asthma‐COPD Overlap Compared to Patients with COPD without Asthma. Biomedicines, 10(7), [1463]. https://doi.org/10.3390/biomedicines10071463

Vancouver

Bonnesen B, Sivapalan P, Jordan A, Pedersen JW, Bergsøe CM, Eklöf J et al. Risk of Malignancy in Patients with Asthma‐COPD Overlap Compared to Patients with COPD without Asthma. Biomedicines. 2022;10(7). 1463. https://doi.org/10.3390/biomedicines10071463

Author

Bonnesen, Barbara ; Sivapalan, Pradeesh ; Jordan, Alexander ; Pedersen, Johannes Wirenfeldt ; Bergsøe, Christina Marisa ; Eklöf, Josefin ; Toennesen, Louise Lindhardt ; Jensen, Sidse Graff ; Naqibullah, Matiullah ; Saghir, Zaigham ; Jensen, Jens Ulrik Stæhr. / Risk of Malignancy in Patients with Asthma‐COPD Overlap Compared to Patients with COPD without Asthma. In: Biomedicines. 2022 ; Vol. 10, No. 7.

Bibtex

@article{53a9ac65c4df4ae49149393714df14c3,

title = "Risk of Malignancy in Patients with Asthma‐COPD Overlap Compared to Patients with COPD without Asthma",

abstract = "Chronic inflammation such as asthma may lead to higher risks of malignancy, which may be inhibited by anti‐inflammatory medicine such as inhaled corticosteroids (ICS). The aim of this study was to evaluate if patients with asthma‐Chronic Obstructive Pulmonary Disease (COPD) overlap have a higher risk of malignancy than patients with COPD without asthma, and, secondarily, if inhaled corticosteroids modify such a risk in a nationwide multi‐center retrospective cohort study of Danish COPD‐outpatients with or without asthma. Patients with asthma‐COPD overlap were propensity score matched (PSM) 1:2 to patients with COPD without asthma. The endpoint was cancer diagnosis within 2 years. Patients were stratified depending on prior malignancy within 5 years. ICS was explored as a possible risk modifier. We included 50,897 outpatients with COPD; 88% without prior malignancy and 20% with asthma. In the PSM cohorts, 26,003 patients without prior malignancy and 3331 patients with prior malignancy were analyzed. There was no association between asthma‐COPD overlap and cancer with hazard ratio (HR) = 0.92, CI = 0.78–1.08, p = 0.31 (no prior malignancy) and HR = 1.04, CI = 0.85–1.26, and p = 0.74 (prior malignancy) as compared to patients with COPD without asthma. ICS did not seem to modify the risk of cancer. In conclusion, in our study, asthma‐COPD overlap was not associated with an increased risk of cancer events.",

keywords = "asthma, asthma‐COPD overlap, cancer, Chronic Obstructive Pulmonary Disease, COPD, ICS, inhaled corticosteroids",

author = "Barbara Bonnesen and Pradeesh Sivapalan and Alexander Jordan and Pedersen, {Johannes Wirenfeldt} and Bergs{\o}e, {Christina Marisa} and Josefin Ekl{\"o}f and Toennesen, {Louise Lindhardt} and Jensen, {Sidse Graff} and Matiullah Naqibullah and Zaigham Saghir and Jensen, {Jens Ulrik St{\ae}hr}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

doi = "10.3390/biomedicines10071463",

language = "English",

volume = "10",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "7",

}

RIS

TY - JOUR

T1 - Risk of Malignancy in Patients with Asthma‐COPD Overlap Compared to Patients with COPD without Asthma

AU - Bonnesen, Barbara

AU - Sivapalan, Pradeesh

AU - Jordan, Alexander

AU - Pedersen, Johannes Wirenfeldt

AU - Bergsøe, Christina Marisa

AU - Eklöf, Josefin

AU - Toennesen, Louise Lindhardt

AU - Jensen, Sidse Graff

AU - Naqibullah, Matiullah

AU - Saghir, Zaigham

AU - Jensen, Jens Ulrik Stæhr

PY - 2022

Y1 - 2022

N2 - Chronic inflammation such as asthma may lead to higher risks of malignancy, which may be inhibited by anti‐inflammatory medicine such as inhaled corticosteroids (ICS). The aim of this study was to evaluate if patients with asthma‐Chronic Obstructive Pulmonary Disease (COPD) overlap have a higher risk of malignancy than patients with COPD without asthma, and, secondarily, if inhaled corticosteroids modify such a risk in a nationwide multi‐center retrospective cohort study of Danish COPD‐outpatients with or without asthma. Patients with asthma‐COPD overlap were propensity score matched (PSM) 1:2 to patients with COPD without asthma. The endpoint was cancer diagnosis within 2 years. Patients were stratified depending on prior malignancy within 5 years. ICS was explored as a possible risk modifier. We included 50,897 outpatients with COPD; 88% without prior malignancy and 20% with asthma. In the PSM cohorts, 26,003 patients without prior malignancy and 3331 patients with prior malignancy were analyzed. There was no association between asthma‐COPD overlap and cancer with hazard ratio (HR) = 0.92, CI = 0.78–1.08, p = 0.31 (no prior malignancy) and HR = 1.04, CI = 0.85–1.26, and p = 0.74 (prior malignancy) as compared to patients with COPD without asthma. ICS did not seem to modify the risk of cancer. In conclusion, in our study, asthma‐COPD overlap was not associated with an increased risk of cancer events.

AB - Chronic inflammation such as asthma may lead to higher risks of malignancy, which may be inhibited by anti‐inflammatory medicine such as inhaled corticosteroids (ICS). The aim of this study was to evaluate if patients with asthma‐Chronic Obstructive Pulmonary Disease (COPD) overlap have a higher risk of malignancy than patients with COPD without asthma, and, secondarily, if inhaled corticosteroids modify such a risk in a nationwide multi‐center retrospective cohort study of Danish COPD‐outpatients with or without asthma. Patients with asthma‐COPD overlap were propensity score matched (PSM) 1:2 to patients with COPD without asthma. The endpoint was cancer diagnosis within 2 years. Patients were stratified depending on prior malignancy within 5 years. ICS was explored as a possible risk modifier. We included 50,897 outpatients with COPD; 88% without prior malignancy and 20% with asthma. In the PSM cohorts, 26,003 patients without prior malignancy and 3331 patients with prior malignancy were analyzed. There was no association between asthma‐COPD overlap and cancer with hazard ratio (HR) = 0.92, CI = 0.78–1.08, p = 0.31 (no prior malignancy) and HR = 1.04, CI = 0.85–1.26, and p = 0.74 (prior malignancy) as compared to patients with COPD without asthma. ICS did not seem to modify the risk of cancer. In conclusion, in our study, asthma‐COPD overlap was not associated with an increased risk of cancer events.

KW - asthma

KW - asthma‐COPD overlap

KW - cancer

KW - Chronic Obstructive Pulmonary Disease

KW - COPD

KW - ICS

KW - inhaled corticosteroids

U2 - 10.3390/biomedicines10071463

DO - 10.3390/biomedicines10071463

M3 - Journal article

C2 - 35884768

AN - SCOPUS:85133159800

VL - 10

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 7

M1 - 1463

ER -

ID: 321875655